Dosimetric and NTCP advantages of robust proton therapy over robust VMAT for Stage III NSCLC in the immunotherapy era-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Dosimetric and NTCP advantages of robust proton therapy over robust VMAT for Stage III NSCLC in the immunotherapy era

Published:2024-07 Issue: Volume:123 Page:103410
ISSN:1120-1797
Container-title:Physica Medica
language:en
Short-container-title:Physica Medica

Author:

Dionisi F.,Landoni V.,Widesott L.,Nardangeli A.,Fracchiolla F.,Siniscalchi B.,Soriani A.,Turkaj A.,Righetto R.^ORCID,Amelio D.^ORCID,Farace P.^ORCID,Goanta L.,Trianni A.,Lorentini S.,Cianchetti M.,Sanguineti G.

Funder

Ministero della Salute

Publisher

Elsevier BV

Reference71 articles.

1. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Sung;CA Cancer J Clin,2021

2. Cancer Tomorrow [Internet]. [cited 2023 Mar 20]. Available from: https://gco.iarc.fr/tomorrow/en/dataviz/bubbles?cancers=15&types=0&sexes=0&group_cancers=1&multiple_cancers=1&single_unit=100000&group_populations=1.

3. Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer;Antonia;The New England Journal of Medicine,2017

4. Five-year survival outcomes with durvalumab after chemoradiotherapy in unresectable stage III NSCLC: An update from the PACIFIC trial;Spigel;JCO,2021

5. Treatment Characteristics and Real-World Progression-Free Survival in Patients With Unresectable Stage III NSCLC Who Received Durvalumab After Chemoradiotherapy: Findings From the PACIFIC-R Study;Girard;J Thorac Oncol,2023

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP